Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor

被引:1
|
作者
Rakotoambinina, B
Médioni, J
Rabian, C
Jubault, V
Jais, JP
Viard, JP
机构
[1] Hop Necker Enfants Malad, Serv Immunol Clin, F-75743 Paris 15, France
[2] Hop Necker Enfants Malad, Dept Biostat, F-75743 Paris 15, France
关键词
lipodystrophy; protease inhibitors; nucleoside analogs; hyperlipidemia; HIV infection;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To assess the frequency and features of lipodystrophic syndromes in HIV-1-infected patients receiving highly active antiretroviral therapy (HAART) with a protease inhibitor (PI), and examine whether clinical and biologic abnormalities are always associated in these conditions. Methods: Retrospective-prospective single-center observational study of 175 patients. Comparisons for continuous variables by t-test and paired t-test, and Kaplan-Meier analysis of time to onset of lipodystrophy were performed. Results: In all, 51 patients (29%) had morphologic changes, after a mean HAART duration of 20.0 +/- 6.1 months, and were categorized into pure lipoatrophy (n = 16), mixed syndrome (truncal fat accumulation and face or limb lipoatrophy) (n = 30) or pure truncal fat accumulation (In = 5). Because of the small number, the latter group was not analyzed statistically. No differences were found among patients with lipoatrophy, mixed syndrome, or no lipodystrophy, in terms of gender, CD4 count, and HIV RNA plasma load at time of HAART initiation, nor in response to treatment. Patients with a mixed syndrome were older. Patients with lipoatrophy had longer duration of HIV disease, pre-HAART exposure to nucleoside analog therapy, and HAART. Baseline and pre-HAART fasting triglyceride levels were higher in patients who developed lipoatrophy, whereas weight and fasting cholesterol were higher in patients who developed a mixed syndrome. After 12 and 24 months on HAART, triglycerides and cholesterol rose significantly in all patients, independently of lipodystrophy, whereas these parameters were not increased during nucleoside analog therapy. Conclusions: Nucleoside analog exposure appears as a risk factor for lipoatrophy. Age and nutritional status (reflected by baseline weight, triglycerides and cholesterol) may influence the evolution to lipoatrophy or a mixed syndrome. Hyperlipidemia is observed in the absence of lipodystrophy and depends on PI exposure.
引用
收藏
页码:443 / 449
页数:7
相关论文
共 50 条
  • [21] Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients
    Bittar, Randa
    Giral, Philippe
    Aslangul, Elisabeth
    Assoumou, Lambert
    Valantin, Marc-Antoine
    Kalmykova, Olga
    Fesel-Fouquier, Valerie
    Costagliola, Dominique
    Bonnefont-Rousselot, Dominique
    ANTIVIRAL THERAPY, 2012, 17 (05) : 855 - 860
  • [22] Effect of Highly Active Antiretroviral Therapy on Homocysteine Plasma Concentrations in HIV-1-Infected Patients
    Coria-Ramirez, Erika
    Nieto Cisneros, Leopoldo
    Trevino-Perez, Sandra
    Ibarra-Gonzalez, Isabel
    Casillas-Rodriguez, Jesus
    Majluf-Cruz, Abraham
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 54 (05) : 477 - 481
  • [23] Sonographically Measured Perirenal Fat Thickness: An Early Predictor of Atherosclerosis in HIV-1-Infected Patients Receiving Highly Active Antiretroviral Therapy?
    Grima, Pierfrancesco
    Guido, Marcello
    Zizza, Antonella
    Chiavaroli, Roberto
    JOURNAL OF CLINICAL ULTRASOUND, 2010, 38 (04) : 190 - 195
  • [24] A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients
    Demeter, Lisa M.
    Jiang, Hongyu
    Mukherjee, A. Lisa
    Morse, Gene D.
    DiFrancesco, Robin
    DiCenzo, Robert
    Dykes, Carrie
    Sista, Prakash
    Bacheler, Lee
    Klingman, Karin
    Rinehart, Alex
    Albrecht, Mary
    AIDS, 2009, 23 (03) : 357 - 368
  • [25] Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
    Fatkenheuer, G
    Theisen, A
    Rockstroh, J
    Grabow, T
    Wicke, C
    Becker, K
    Wieland, U
    Pfister, H
    Reiser, M
    Hegener, P
    Franzen, C
    Schwenk, A
    Salzberger, B
    AIDS, 1997, 11 (14) : F113 - F116
  • [26] Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy
    Schouten, Judith
    Su, Tanja
    Wit, Ferdinand W.
    Kootstra, Neeltje A.
    Caan, Matthan W. A.
    Geurtsen, Gert J.
    Schmand, Ben A.
    Stolte, Ineke G.
    Prins, Maria
    Majoie, Charles B.
    Portegies, Peter
    Reiss, Peter
    AIDS, 2016, 30 (07) : 1027 - 1038
  • [27] Effect of antiretroviral therapy use and adherence on the risk of hyperlipidemia among HIV-infected patients, in the highly active antiretroviral therapy era
    Tsai, Fuu-Jen
    Cheng, Chi-Fung
    Lai, Chih-Ho
    Wu, Yang-Chang
    Ho, Mao-Wang
    Wang, Jen-Hsien
    Tien, Ni
    Liu, Xiang
    Tsang, Hsinyi
    Lin, Ting-Hsu
    Liao, Chiu-Chu
    Huang, Shao-Mei
    Li, Ju-Pi
    Lin, Jung-Chun
    Lin, Chih-Chien
    Chen, Jin-Hua
    Liang, Wen-Miin
    Lin, Ying-Ju
    ONCOTARGET, 2017, 8 (63) : 106369 - 106381
  • [28] Reasons for not starting antiretroviral therapy in HIV-1-infected individuals: a changing landscape
    Jan Fehr
    Dunja Nicca
    Jean-Christophe Goffard
    David Haerry
    Michael Schlag
    Vasileios Papastamopoulos
    Andy Hoepelman
    Athanasius Skoutelis
    Ruth Diazaraque
    Bruno Ledergerber
    Infection, 2016, 44 : 521 - 529
  • [29] Reasons for not starting antiretroviral therapy in HIV-1-infected individuals: a changing landscape
    Fehr, Jan
    Nicca, Dunja
    Goffard, Jean-Christophe
    Haerry, David
    Schlag, Michael
    Papastamopoulos, Vasileios
    Hoepelman, Andy
    Skoutelis, Athanasius
    Diazaraque, Ruth
    Ledergerber, Bruno
    INFECTION, 2016, 44 (04) : 521 - 529
  • [30] Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy - The Swiss HIV Cohort Study
    Friedl, AC
    Ledergerber, B
    Flepp, M
    Hirschel, B
    Telenti, A
    Furrer, H
    Bucher, HC
    Bernasconi, E
    Weber, R
    AIDS, 2001, 15 (14) : 1793 - 1800